Ectonucleotidases in Inflammation, Immunity, and Cancer

Clarissa Branco Haas, Marianna Lovászi, Elizandra Braganhol, Pál Pacher and György Haskó
J Immunol May 1, 2021, 206 (9) 1983-1990; DOI: https://doi.org/10.4049/jimmunol.2001342

Abstract

Nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of enzymes that hydrolyze nucleotides such as ATP, UTP, ADP, and UDP to monophosphates derivates such as AMP and UMP. The NTPDase family consists of eight enzymes, of which NTPDases 1, 2, 3, and 8 are expressed on cell membranes thereby hydrolyzing extracellular nucleotides. Cell membrane NTPDases are expressed in all tissues, in which they regulate essential physiological tissue functions such as development, blood flow, hormone secretion, and neurotransmitter release. They do so by modulating nucleotide-mediated purinergic signaling through P2 purinergic receptors. NTPDases 1, 2, 3, and 8 also play a key role during infection, inflammation, injury, and cancer. Under these conditions, NTPDases can contribute and control the pathophysiology of infectious, inflammatory diseases and cancer. In this review, we discuss the role of NTPDases, focusing on the less understood NTPDases 2–8, in regulating inflammation and immunity during infectious, inflammatory diseases, and cancer.

Introduction

Following the realization that ATP is released together with classical neurotransmitters, including acetylcholine and glutamate, in both the peripheral nervous system and CNS (1–3), ATP was demonstrated to be an extracellular signaling molecule involved in the regulation of a variety of physiological and pathophysiological processes, such as blood flow, cell death, and inflammation (4). Subsequent studies have demonstrated that in addition to ATP, other nucleotides such as ADP, UTP, UDP, and UDP-sugars can also serve as extracellular signaling molecules. Cell stress, cell death, and inflammation are common events that trigger extracellular nucleotide release (5). Nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of enzymesconsisting of eight members, denoted NTPDases 1–8, that hydrolyzes nucleotides (6). Four enzymes, NTPDase1/CD39, NTPDase2/CD39L1, NTPDase3/CD39L3, and NTPDase8, are cell membrane–bound enzymes that face the extracellular matrix and therefore are able to degrade extracellular nucleotides (Fig. 1). Therefore, these enzymes can control the bioavailability of purines and signaling through P2 receptors in the extracellular space (7–16). The final products of NTPDase-mediated nucleotide hydrolysis are nucleoside monophosphates, such as AMP and UMP, which are further metabolized in the extracellular space by ectoenzymes, such as CD73, to adenosine and uridine, respectively (6). Adenosine has tissue-protective, -immunosuppressive, and –anti-inflammatory functions through P1 or adenosine (1–3) receptors signaling (6, 17–25), whereas uridine has no known receptors (26). Thus, membrane surface NTPDases together with CD73 eventually switch the extracellular milieu microenvironment from pro- to anti-inflammatory (27–34). Unlike NTPDases 1 and 3 where ADP is not released from the enzymes during nucleotide catabolism to AMP or UMP, respectively, NTPDase2 and NTPDase8 can release ADP and UDP transiently, which can have at least transient, proinflammatory, and prothrombotic effects through P2 receptors on immune cells and platelets (16, 35). Eventually, this ADP and UDP will be further degraded to AMP and UMP and then adenosine and uridine, respectively, thereby suppressing inflammation.

FIGURE 1.
FIGURE 1.

Cellular localization and function of E-NTPDase isotypes. NTPDases 1, 2, 3, and 8 are transmembrane enzymes that face the extracellular milieu. NTPDases 4, 5, 6, and 7 are localized in the intracellular milieu. NTPDase4 is expressed in lysosomes and autophagic vacuole. NTPDase5 is expressed in the ER. NTPDase6 is expressed in the Golgi apparatus, and NTPDase7 is expressed in vesicles. Created with BioRender.com.

The first NTPDase identified was CD39, which later was renamed NTPDase1 while other enzymes of the NTPDase family began to be uncovered (7, 8). NTPDases are expressed in all tissues and regulate essential functions such as development, blood flow, and hormone secretion (6). NTPDases have five “apyrase conserved regions” (ACR1 to ACR5) involved in the catalytic cycle (36). NTPDases 1, 2, 3, and 8 have two transmembrane domains, which together with the extracellular domains control substrate specificity during nucleotide binding and hydrolysis (6). Additionally, NTPDases require Ca2+ and Mg2+ as cofactors and thus alterations of Ca2+ and Mg2+ concentrations can alter enzyme activity.

NTPDases 4, 5, 6, and 7 are localized in the intracellular space where they are anchored to intracellular organelle membranes or vesicles and have lower affinity to nucleotides when compared with extracellular ones (37) (Fig. 1). NTPDases 5 and 6 are anchored to the organelles by one transmembrane domain, whereas NTPDases 4 and 7 are anchored to the organelles by two transmembrane domains (38, 39).

In this review, we will discuss the role of NTPDases in inflammation, immunity, and cancer. Because the role of NTPDase1 has been already studied and is the subject of many excellent reviews (30, 38, 40–44), our goal is to summarize recent literature on the role of NTPDases 2–8, for which NTPDase1 will serve as a reference point. We first outline which cellular compartments, tissue, and organs express the various extra and intracellular NTPDases. We then discuss the role of NTPDases in regulating infectious and inflammatory diseases and cancer. Finally, we provide a short perspective on the possible therapeutic value of targeting NTPDases for the treatment of infectious and inflammatory diseases and cancer.

Cell, tissue, and organ expression of extracellular NTPDases

Extracellular NTPDases are found in different tissues in which they have distinct functions based on their localization. NTPDase1/CD39 (ATPDase/ectoapyrase) is expressed in human vascular tissue, liver, spleen, peripheral blood leukocytes, and lungs (7, 8). Diverse cell types including vascular endothelial cells, regulatory T cells, macrophages, Langerhans cells, and NK cells express NTPDase1 (45, 46). Several reviews have summarized in detail the role of CD39 in inflammation and immunity (30, 38, 40–43), and in this review, we will primarily focus on the other NTPDases.

NTPDases 1 and 2 are expressed together in blood vessels where NTPDase1 is found primarily on endothelial and smooth muscle cells and NTPDase2 is found on adventitial cells and portal fibroblasts (6). NTPDases 1 and 2 have different enzymatic activities and, therefore, functions. NTPDase1 hydrolyzes ATP directly to AMP, without any significant accumulation of ADP (35), whereas NTPDase2 first produces ADP and then slowly generates AMP (47). In the liver, which has one of the highest ATPase and ADPase activities of all organs, NTPDase1 is expressed on Kupffer and vascular endothelial cells and NTPDase2 is found on portal fibroblasts and activated hepatic stellate cells (16).

Besides the liver, NTPDase2 is highly expressed in the brain, muscles, testis, and at lower levels, in the lungs. In the brain, it was described to be related to neural development and differentiation (48). It is also expressed by type I cells of taste buds, in which it regulates ATP levels and, therefore, gustation (49). Both NTPDase2 and NTPDase3 are expressed on cells of the enteric nervous system (ENS) in both murine and human colon (50). NTPDase3 can be detected in the rat brain on neurons related to feeding and sleep-wake behavior (51). It was also reported that NTPDase3 expression is specific to human pancreatic β-cells (52) and can regulate insulin secretion (53). NTPDase3 together with NTPDase1 is distributed in human airways in which these enzymes have a major role in regulating nucleotide concentrations in the airway surface liquid layer (54, 55). NTPDases 3 and 8 have higher affinity to ATP/UTP over ADP/UDP when compared with NTPDases 1 and 2 (35). NTPDase8 (liver canalicular ecto-ATPase/hATPase) was the last NTPDase characterized (15) and it is expressed mainly in the liver, followed by the intestine and kidney (15, 16). In the liver, NTPDase8 is found in bile canaliculi where it is involved in bile flow regulation and is likely involved in purine reuptake and salvage by hepatocytes (16). Because the liver is a major metabolic and immune organ with important roles in immunological and inflammatory diseases, such as sepsis (56), the function of NTPDade8 in metabolism, immunology, and inflammation will be the subject of future studies. A synthesis of our knowledge of NTPDase cellular localization, tissue expression, and function can be found in Table I.

View this table:
Table I.

Cellular localization and tissue expression of E-NTPDase isotypes

Cell, tissue, and organ expression of intracellular NTPDases

NTPDases 4, 5, 6, and 7 are localized intracellularly and regulate levels of nucleotides/nucleosides within organelles. NTPDase4 (Golgi UDPase/LALP70) is anchored to the Golgi apparatus, and hence has been named Golgi UDPase (38). A second variant of NTPDase4 was reported to be expressed in lysosomes and autophagic vacuoles (57). NTPDase5 (CD39L4/ER-UDPase) is found in the endoplasmic reticulum (ER) (58). Reglucosylation reactions involved in glycoprotein folding and quality control take place in the ER and UDP is generated in the lumen from the UDP-Glucose that is translocated from the cytosol (59). A soluble form of NTPDase5 called ER-UDPase was described in vitro, and it was found to metabolize UDP, thereby preventing accumulation of inhibitory levels of UDP that could negatively interfere with the reglucosylation process (60). NTPDase5 is also a protooncogene known as PCPH (61). Both NTPDases 5 and 6 are expressed in the rat cochlea and can also be found in the cochlear fluid. NTPDase5 is localized to the spiral ganglion neurons and supporting Deiters cells in the organ of Corti and it appears to have a role in the cochlear response to stress (62). NTPDase6 (CD39L2) that is mostly associated with the Golgi and to a small extent with the cell membrane but can also be found in cell supernatants (63). It is highly expressed intracellularly in the heart and vasculature (57, 64, 65). In the cochlea, NTPDase6 is found in vestibular hair cells and it was proposed to be involved in vestibular sensory transduction (66). NTPDase7 (LALP1) is widely expressed in intracellular vesicles in tissues (38), but its function is poorly understood.

NTPDase expression in immune cells

NTPDase1 was first identified in B lymphocytes (45) and later in T lymphocytes (67). Although NTPDase1 function has been extensively studied in immune cells (31, 41, 43, 68, 69), less is known about the role of NTPDases 2–8 in immunity. Similar to NTPDase1 (70), NTPDases 2 and 3 are also expressed in naive peritoneal macrophages (71). NTPDase1 and 3 expression in macrophages varies depending on whether macrophages exhibit a proinflammatory M1 or anti-inflammatory M2 phenotype, whereas no differences in NTPDase2 are noted between these two major macrophage phenotypes (71). In the blood, extracellular NTPDase2 was also found highly expressed in eosinophils (72). An important expression of NTPDase3 is also found in dendritic cells (72). NTPDase5 is found in eosinophils and basophils (72). The expression of NTPDases 4, 6, 7, and 8 has not been reported in immune cells. A synthesis of our knowledge of the NTPDase expression in immune cells is presented in Fig. 2.

FIGURE 2.
FIGURE 2.

NTPDase expression and function in innate and adaptative immune cells. Created with BioRender.com.

Infectious diseases

Ectonucleotidase activity contributes to the promotion of infection caused by the parasite Leishmania, which can modulate host immune responses to promote disease progression (73). The expression of endothelial cell NTPDases 2 and 3 is increased upon infection with Schistosoma mansoni, which results in increased ATP hydrolysis to ADP. Higher concentrations of ADP increase ICAM-1 expression and mononuclear cell adhesion to the endothelial cells through activating P2Y1 receptors (74). The authors of this study proposed that increased inflammation secondary to increased monocyte adhesion is likely to contribute to morbidity in Schistosoma (74).

In a model of bacterial infection using primary cultures of human bronchial epithelial cells treated with Pseudomonas aeruginosa LPS, the mRNA level of both NTPDase1 and NTPDase3 was increased 24h after treatment (54). In another study, exposure of airway epithelial cells to supernatant of the mucopurulent material collected from cystic fibrosis patients increased NTPDase3 activity and expression (55).

We demonstrated for the first time that NTPDase1 increased survival in mice suffering from polymicrobial sepsis, which was secondary to decreased inflammation and infection, organ damage and cellular apoptosis (34). The protective role of CD39 in polymicrobial sepsis was confirmed in a subsequent study (75). Another study reported increased ATP but not ADP hydrolysis in neutrophils isolated from rats undergoing polymicrobial sepsis (76). This indicates that the function of distinct NTPDases is differentially regulated in neutrophils during sepsis. The precise roles of NTPDases 2–8 have yet to be determined in bacteremia and sepsis.

Chronic inflammatory diseases

NTPDases have emerged as promising targets for the treatment of inflammatory diseases. The role of NTPDases in regulating inflammation in the intestine has received much attention. NTPDases 1, 2, 3, and 8 are all expressed in the gut, where they have all been associated with blood vessels (77). NTPDase1 single-nucleotide polymorphisms tagging low levels of NTPDase1 expression are associated with increased susceptibility to inflammatory bowel disease (IBD) in humans (78). NTPDases 2 and 3 are expressed by both the human and murine ENSs (50). It was demonstrated that the gene expression of NTPDases 1, 3, and 7 was upregulated in human colon areas affected by ulcerative colitis when compared with healthy colon areas (79). Recently, it was demonstrated that primary intestinal epithelial cells cultivated in vitro express NTPDases 3 and 8 (80).

General NTPDase inhibition using the nonselective inhibitor polyoxotungstate-1 augmented intestinal injury in mice treated with dextran sulfate sodium (DSS), indicating a protective role for NTPDases (79). In another murine study, NTPDases 2 and 3 were found predominantly expressed in the ENS (50). Genetic deletion of NTPDase2 but not NTPDase3 increased the severity of DSS-induced colitis, and macrophages in NTPDase2-deficient mice had increased expression of the activation markers CD68 and MHC class II (50). Grubišić and colleagues confirmed the anti-inflammatory role of NTPDase2 in DSS-induced colitis in mice, where NTPDase2 suppressed gut permeability and normalized gut motility (65). It was demonstrated that nonselective NTPDase inhibition exacerbated tissue damage in DSS-induced colitis in mice, which was associated with a lower frequency of IL-22–producing innate lymphoid cell type 3 (ILC3) in the gut. The same study showed that intestinal or splenic ILC3s challenged with extracellular ATP had decreased IL-22 production, whereas apyrase-mediated ATP breakdown increased IL-22 production by splenic ILC3s (79). However, it is unclear which NTPDase was targeted by apyrase in this study.

NTPDase7 deficiency in mice increased levels of ATP in the small intestinal lumen and increased the number of Th17 lymphocytes in the lamina propria (81). This increase in Th17 cells was reversed by the P2 receptor antagonist oxidized ATP as well as antibiotics. The authors speculated that microbially released ATP mediates the increased Th17 cell development in NTPDase7-deficient mice. Consistent with this, NTPDase7-deficient mice were resistant to oral infection with Citrobacter rodentium, a model in which Th17 cells are protective and developed severe experimental allergic encephalomyelitis where Th17 are responsible for pathogenesis (81). Although these are interesting observations, further studies will need to investigate how deficiency of NTPDase7, an intracellular NTPDase, leads to increased ATP levels extracellularly. Recent evidence has demonstrated that NTPDase8 hydrolyzes nucleotides at the apical surface of mouse colonic epithelium and that it is an important player in the protection of the intestine from inflammation (80). NTPDase8-deficient mice presented with a worse outcome in DSS-induced colitis when compared with WT mice. This worse outcome was due to increased P2Y6 activation causing increased inflammation at the intestinal apical surface during colitis (80).

Although NTPDase3 activity is higher in primary bronchial epithelial cell cultures from patients suffering from chronic lung disease (54), the clinical significance of this finding is unclear at this point. NTPDase2 is expressed on portal fibroblasts in the liver (82). After chronic carbon tetrachloride intoxication, a model of liver fibrosis, NTPDase2-deficient mice exhibit more severe liver fibrosis. In contrast, NTPDase2-deficient mice do not have altered responses to the fibrotic agent 3,5-diethoxycarbonyl-1,4-dihydrocollidine or partial hepatectomy when compared with control, wild-type mice (83).

Multiple sclerosis (MS) is a demyelinating disease, which is caused by an immune response to myelin. Patients with MS have reduced CD39+/NTPDase1+ T regulatory cell counts in the blood (84). Studies in mice employing the MS model experimental autoimmune encephalomyelitis have indicated that NTPDase1 limits the course of MS (30). A recent study demonstrated that NTPDase2 levels decrease in the spinal cord during experimental autoimmune encephalomyelitis in mice and that this decrease is associated with the severity of disease (85). The precise roles of the various NTPDase isotypes and their potential as targets for the treatment of chronic inflammatory diseases need to be further investigated.

Cancer

Increasing evidence supports the notion that the presence of a chronic inflammatory environment, characterized by immune cell infiltrates and their secretion of inflammatory mediators is fundamental for tumor progression (86). Purinergic signaling orchestrates immune/inflammatory response and its dysfunction has also been described in a variety of tumors, including breast cancer, melanoma, and glioblastoma (29, 87). Indeed, increased ATP and adenosine concentrations in the tumor microenvironment are emerging as key mediators of cancer-related inflammation, promoting tumor progression as well as immune escape (88). ATP accumulates in the tumor microenvironment as a combination of processes, including release by cell death, as a result of cancer growth/invasion, or following radiochemotherapy treatment (89). These increased levels of ATP can have protumor activities (90).

In glioblastoma, the most common and aggressive type of tumor found in the brain, both NTPDase expression and activity are downregulated when compared with astrocytes, which express abundant levels of NTPDase2 (91). Treatment of glioma cells with apyrase, a nucleotidase isolated from the potato plant that is similar to NTPDases, reduces in vitro glioma proliferation through preventing P2Y6 and P2X7 stimulation and IL-8 and MCP-1 production (92). Similarly, treatment of glioma cells with apyrase impaired in vivo tumor growth in a preclinical glioblastoma model (93). In contrast, by overexpressing NTPDase2, we demonstrated that ADP derived from NTPDase2 activity stimulates platelet migration to the tumor area and, by regulating angiogenesis and inflammation, promotes glioma progression (94). NTPDase2 overexpression in gliomas also induced peripheral inflammation, as evidenced by higher plasma concentrations of IL-1β/TNF-α/IL-6, increased platelet reactivity, and pathological alterations on lung tissue suggestive of tumor spread (95). Because NTPDase2 produces ADP and apyrase AMP, the differential effects of NTPDase2 and apyrase in glioma are likely related to these different nucleotides.

Another member of the NTPDase family associated with tumor progression is NTPDase5/PCPH. PCPH was originally identified as a protooncogene that is converted to an oncogene by a single base pair deletion, resulting in a mutated protein (PCPH-mt) (61). PCPH is structurally and functionally identical to NTPDase5 (61) and its expression has been reported in a variety of tumors, including breast (96), prostate (97), bladder cancer (98) and glioblastoma (93). Loss of function of ENTPD5 causes higher turnover of hepatocytes and promotes hepatocellular oncogenesis (99). In accordance with its intrinsic ATP diphosphohydrolase activity, PCPH-mt has been shown to deplete intracellular ATP and consequently inhibit c-JUN NH2-terminal kinase-mediated stress signaling pathways. The restoration of ATP levels recovered both stress-response signaling and sensitivity to chemotherapy-induced apoptosis (100). A comparative study of purinergic signaling in the RT4 and T24 cancer cell lines, demonstrated differential NTPDase regulation and nucleotide metabolism (98). In RT4 cells, the hydrolysis of tri- and diphosphate nucleosides was higher than that of monophosphonucleosides. T24 cells, however, presented with low level of hydrolysis of tri- and diphosphate nucleosides and a high level of hydrolysis of monophosphates. This is consistent with observations that T24 cells only expressed the intracellular NTPDase5 mRNA, whereas the RT4 cells expressed both the extracellular NTPDase3 and, to a lesser extent, NTPDase5 mRNA. In a preclinical model of bladder cancer, a progressive decrease of NTPDase3 expression was found (101). Taken together, these data suggest that the impairment of extracellular nucleotide metabolism as a result of NTPDase downregulation and/or the expression of NTPDase5/mt-PCPH can modulate the initiation, establishment, and/or progression of tumors by modulating both cancer cell proliferation and cancer-stroma cross-talk.

Conclusions

Our understanding of the role of NTPDases 2–8 in inflammation, immunity, and cancer has been expanding in recent years. Gene-deficient mouse models are increasingly becoming available for these enzymes, which should facilitate the identification of functions for NTPDases 2–8. In this respect, the role of extracellular nucleotidases 2, 3, and 8 in intestinal chronic inflammatory disease is especially captivating and has attracted much interest (50, 65, 78–80). Because NTPDases 2 (50, 65) and 8 (80) knockout mice presented worse outcomes in experimental models of IBD, enteric administration of these enzymes may present a new therapeutical approach for patients with IBD. Because NTPDase3 activity is higher in bronchial epithelial cells from patients with chronic lung disease (54) and NTPDase2 levels were decreased in the spinal cord of mice with experimental autoimmune encephalomyelitis (85), it will be important to study the role NTPDase3 and NTPDase2 in chronic inflammatory lung disease and MS models, respectively.

Previous data also demonstrated a role of NTPDase2 in glioblastoma progression in vitro and in vivo (92, 94, 95). Mice deficient for NTPDase2 thus will be useful for uncovering more specific cellular mechanisms of NTPDase2 in the context of glioblastoma. These studies could establish NTPDase2 as a target for the treatment of glioblastoma as well as other tumors.

There is also progress in developing specific enzyme inhibitors (102), which will be helpful in characterizing the immunomodulatory functions of the various NTPDases. It will also be important to study in detail which immune cell types express NTPDases 2–8 and how their expression is regulated. Another important gap in the current knowledge is how NTPDases 2–8 function in conjunction with purinergic receptors. Given the enormous promise of targeting NTPDase1 and CD73 in the therapy of immune diseases (103, 104) and inflammation, we anticipate that NTPDases 2–8 will be the focus of future pharmacological approaches to treat inflammatory, immune diseases and cancer.

Disclosures

G.H. owns stock in Purine Pharmaceuticals, Inc. and has a patent to develop NTPDases for the treatment of sepsis. The other authors have no financial conflicts of interest.

Footnotes

  • This work was supported by Foundation for the National Institutes of Health Grants R01GM06618916 and R01DK11379004.

  • Abbreviations used in this article:

    DSS
    dextran sulfate sodium
    ENS
    enteric nervous system
    ER
    endoplasmic reticulum
    IBD
    inflammatory bowel disease
    ILC3
    innate lymphoid cell type 3
    MS
    multiple sclerosis
    NTPDase
    nucleoside triphosphate diphosphohydrolase.

  • Received November 30, 2020.
  • Accepted February 2, 2021.

References

  1. ↵
    2. Su, C.
    3. J. A.Bevan
    4. G.Burnstock
    . 1971. [3H]adenosine triphosphate: release during stimulation of enteric nerves. Science 173: 336–338.
    OpenUrlAbstract/FREE Full Text
    2. Burnstock, G.
    1972. Purinergic nerves. Pharmacol. Rev. 24: 509–581.
    OpenUrlFREE Full Text
  3. ↵
    2. Burnstock, G.
    2006. Historical review: ATP as a neurotransmitter. Trends Pharmacol. Sci. 27: 166–176.
    OpenUrlCrossRefPubMed
  4. ↵
    2. Bagatini, M. D.
    3. A. A.Dos Santos
    4. A. M.Cardoso
    5. A.Mânica
    6. C. R.Reschke
    7. F. B.Carvalho
    . 2018. The impact of purinergic system enzymes on noncommunicable, neurological, and degenerative diseases. J. Immunol. Res. 2018: 4892473.
    OpenUrl
  5. ↵
    2. Giuliani, A. L.
    3. A. C.Sarti
    4. F.Di Virgilio
    . 2019. Extracellular nucleotides and nucleosides as signalling molecules. Immunol. Lett. 205: 16–24.
    OpenUrlCrossRef
  6. ↵
    2. Robson, S. C.
    3. J.Sévigny
    4. H.Zimmermann
    . 2006. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2: 409–430.
    OpenUrlCrossRefPubMed
  7. ↵
    2. Kaczmarek, E.
    3. K.Koziak
    4. J.Sévigny
    5. J. B.Siegel
    6. J.Anrather
    7. A. R.Beaudoin
    8. F. H.Bach
    9. S. C.Robson
    . 1996. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J. Biol. Chem. 271: 33116–33122.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    2. Chadwick, B. P.
    3. A. M.Frischauf
    . 1998. The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster. Genomics 50: 357–367.
    OpenUrlCrossRefPubMed
    2. Wang, T. F.
    3. P. A.Rosenberg
    4. G.Guidotti
    . 1997. Characterization of brain ecto-apyrase: evidence for only one ecto-apyrase (CD39) gene. Brain Res. Mol. Brain Res. 47: 295–302.
    OpenUrlCrossRefPubMed
    2. Lemmens, R.
    3. L.Vanduffel
    4. A.Kittel
    5. A. R.Beaudoin
    6. O.Benrezzak
    7. J.Sévigny
    . 2000. Distribution, cloning, and characterization of porcine nucleoside triphosphate diphosphohydrolase-1. Eur. J. Biochem. 267: 4106–4114.
    OpenUrlPubMed
    2. Mateo, J.
    3. T. K.Harden
    4. J. L.Boyer
    . 1999. Functional expression of a cDNA encoding a human ecto-ATPase. Br. J. Pharmacol. 128: 396–402.
    OpenUrlCrossRefPubMed
    2. Smith, T. M.
    3. T. L.Kirley
    . 1998. Cloning, sequencing, and expression of a human brain ecto-apyrase related to both the ecto-ATPases and CD39 ecto-apyrases1. Biochim. Biophys. Acta 1386: 65–78.
    OpenUrlCrossRefPubMed
    2. Vorhoff, T.
    3. H.Zimmermann
    4. J.Pelletier
    5. J.Sévigny
    6. N.Braun
    . 2005. Cloning and characterization of the ecto-nucleotidase NTPDase3 from rat brain: predicted secondary structure and relation to other members of the E-NTPDase family and actin. Purinergic Signal. 1: 259–270.
    OpenUrlCrossRefPubMed
    2. Lavoie, E. G.
    3. F.Kukulski
    4. S. A.Lévesque
    5. J.Lecka
    6. J.Sévigny
    . 2004. Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-3. Biochem. Pharmacol. 67: 1917–1926.
    OpenUrlCrossRefPubMed
  15. ↵
    2. Bigonnesse, F.
    3. S. A.Lévesque
    4. F.Kukulski
    5. J.Lecka
    6. S. C.Robson
    7. M. J.Fernandes
    8. J.Sévigny
    . 2004. Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. Biochemistry 43: 5511–5519.
    OpenUrlCrossRefPubMed
  16. ↵
    2. Fausther, M.
    3. J.Lecka
    4. F.Kukulski
    5. S. A.Lévesque
    6. J.Pelletier
    7. H.Zimmermann
    8. J. A.Dranoff
    9. J.Sévigny
    . 2007. Cloning, purification, and identification of the liver canalicular ecto-ATPase as NTPDase8. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G785–G795.
    OpenUrlCrossRefPubMed
  17. ↵
    2. Haskó, G.
    3. C.Szabó
    4. Z. H.Németh
    5. V.Kvetan
    6. S. M.Pastores
    7. E. S.Vizi
    . 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157: 4634–4640.
    OpenUrlAbstract
    2. Haskó, G.
    3. D. G.Kuhel
    4. J. F.Chen
    5. M. A.Schwarzschild
    6. E. A.Deitch
    7. J. G.Mabley
    8. A.Marton
    9. C.Szabó
    . 2000. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14: 2065–2074.
    OpenUrlCrossRefPubMed
    2. Csóka, B.
    3. L.Himer
    4. Z.Selmeczy
    5. E. S.Vizi
    6. P.Pacher
    7. C.Ledent
    8. E. A.Deitch
    9. Z.Spolarics
    10. Z. H.Németh
    11. G.Haskó
    . 2008. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 22: 3491–3499.
    OpenUrlCrossRefPubMed
    2. Csóka, B.
    3. Z. H.Németh
    4. L.Virág
    5. P.Gergely
    6. S. J.Leibovich
    7. P.Pacher
    8. C. X.Sun
    9. M. R.Blackburn
    10. E. S.Vizi
    11. E. A.Deitch
    12. G.Haskó
    . 2007. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 110: 2685–2695.
    OpenUrlAbstract/FREE Full Text
    2. Csóka, B.
    3. Z.Selmeczy
    4. B.Koscsó
    5. Z. H.Németh
    6. P.Pacher
    7. P. J.Murray
    8. D.Kepka-Lenhart
    9. S. M.Morris Jr..
    10. W. C.Gause
    11. S. J.Leibovich
    12. G.Haskó
    . 2011. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 26: 376–386.
    OpenUrl
    2. Németh, Z. H.
    3. B.Csóka
    4. J.Wilmanski
    5. D.Xu
    6. Q.Lu
    7. C.Ledent
    8. E. A.Deitch
    9. P.Pacher
    10. Z.Spolarics
    11. G.Haskó
    . 2006. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J. Immunol. 176: 5616–5626.
    OpenUrlAbstract/FREE Full Text
    2. Csóka, B.
    3. B.Koscsó
    4. G.Töro
    5. E.Kókai
    6. L.Virág
    7. Z. H.Németh
    8. P.Pacher
    9. P.Bai
    10. G.Haskó
    . 2013. A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation. Diabetes 63: 850–866.
    OpenUrl
    2. Csóka, B.
    3. Z. H.Németh
    4. P.Rosenberger
    5. H. K.Eltzschig
    6. Z.Spolarics
    7. P.Pacher
    8. Z.Selmeczy
    9. B.Koscsó
    10. L.Himer
    11. E. S.Vizi, et al
    . 2010. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J. Immunol. 185: 542–550.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    2. Koscsó, B.
    3. B.Csóka
    4. Z.Selmeczy
    5. L.Himer
    6. P.Pacher
    7. L.Virág
    8. G.Haskó
    . 2011. Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J. Immunol. 188: 445–453.
    OpenUrl
  26. ↵
    2. Connolly, G. P.
    3. J. A.Duley
    . 1999. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol. Sci. 20: 218–225.
    OpenUrlCrossRefPubMed
  27. ↵
    2. Antonioli, L.
    3. C.Blandizzi
    4. B.Csóka
    5. P.Pacher
    6. G.Haskó
    . 2015. Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations. Nat. Rev. Endocrinol. 11: 228–241.
    OpenUrlCrossRef
    2. Antonioli, L.
    3. C.Blandizzi
    4. M.Fornai
    5. P.Pacher
    6. H. T.Lee
    7. G.Haskó
    . 2019. P2X4 receptors, immunity, and sepsis. Curr. Opin. Pharmacol. 47: 65–74.
    OpenUrl
  29. ↵
    2. Antonioli, L.
    3. C.Blandizzi
    4. P.Pacher
    5. G.Haskó
    . 2013. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13: 842–857.
    OpenUrlCrossRefPubMed
  30. ↵
    2. Antonioli, L.
    3. C.Blandizzi
    4. P.Pacher
    5. G.Haskó
    . 2019. The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases. Pharmacol. Rev. 71: 345–382.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    2. Antonioli, L.
    3. P.Pacher
    4. E. S.Vizi
    5. G.Haskó
    . 2013. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19: 355–367.
    OpenUrlCrossRefPubMed
    2. Csóka, B.
    3. Z. H.Németh
    4. G.Törő
    5. M.Idzko
    6. A.Zech
    7. B.Koscsó
    8. Z.Spolarics
    9. L.Antonioli
    10. K.Cseri
    11. K.Erdélyi, et al
    . 2015. Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. FASEB J. 29: 3626–3637.
    OpenUrlCrossRefPubMed
    2. Haskó, G.
    3. B.Csóka
    4. B.Koscsó
    5. R.Chandra
    6. P.Pacher
    7. L. F.Thompson
    8. E. A.Deitch
    9. Z.Spolarics
    10. L.Virág
    11. P.Gergely, et al
    . 2011. Ecto-5'-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J. Immunol. 187: 4256–4267.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    2. Csóka, B.
    3. Z. H.Németh
    4. G.Törő
    5. B.Koscsó
    6. E.Kókai
    7. S. C.Robson
    8. K.Enjyoji
    9. R. H.Rolandelli
    10. K.Erdélyi
    11. P.Pacher
    12. G.Haskó
    . 2014. CD39 improves survival in microbial sepsis by attenuating systemic inflammation. FASEB J. 29: 25–36.
    OpenUrl
  35. ↵
    2. Kukulski, F.
    3. S. A.Lévesque
    4. E. G.Lavoie
    5. J.Lecka
    6. F.Bigonnesse
    7. A. F.Knowles
    8. S. C.Robson
    9. T. L.Kirley
    10. J.Sévigny
    . 2005. Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal. 1: 193–204.
    OpenUrlCrossRefPubMed
  36. ↵
    2. Kirley, T. L.
    3. P. A.Crawford
    4. T. M.Smith
    . 2006. The structure of the nucleoside triphosphate diphosphohydrolases (NTPDases) as revealed by mutagenic and computational modeling analyses. Purinergic Signal. 2: 379–389.
    OpenUrlCrossRefPubMed
  37. ↵
    2. Pelletier, J.
    3. M.Salem
    4. J.Lecka
    5. M.Fausther
    6. F.Bigonnesse
    7. J.Sévigny
    . 2017. Generation and characterization of specific antibodies to the murine and human ectonucleotidase NTPDase8. Front. Pharmacol. 8: 115.
    OpenUrlPubMed
  38. ↵
    2. Knowles, A. F.
    2011. The GDA1_CD39 superfamily: NTPDases with diverse functions. Purinergic Signal. 7: 21–45.
    OpenUrlCrossRefPubMed
  39. ↵
    2. Zimmermann, H.
    2001. Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev. Res. 52: 44–56.
    OpenUrlCrossRef
  40. ↵
    2. Dwyer, K. M.
    3. S.Deaglio
    4. W.Gao
    5. D.Friedman
    6. T. B.Strom
    7. S. C.Robson
    . 2007. CD39 and control of cellular immune responses. Purinergic Signal. 3: 171–180.
    OpenUrlCrossRefPubMed
  41. ↵
    2. Kanthi, Y. M.
    3. N. R.Sutton
    4. D. J.Pinsky
    . 2014. CD39: interface between vascular thrombosis and inflammation. Curr. Atheroscler. Rep. 16: 425.
    OpenUrlCrossRefPubMed
    2. Takenaka, M. C.
    3. S.Robson
    4. F. J.Quintana
    . 2016. Regulation of the T cell response by CD39. Trends Immunol. 37: 427–439.
    OpenUrl
  43. ↵
    2. Zhao, H.
    3. C.Bo
    4. Y.Kang
    5. H.Li
    . 2017. What else can CD39 tell us? Front. Immunol. 8: 727.
    OpenUrlCrossRef
  44. ↵
    2. Vuerich, M.
    3. S. C.Robson
    4. M. S.Longhi
    . 2019. Ectonucleotidases in Intestinal and Hepatic Inflammation. Front. Immunol. 10: 507.
    OpenUrlCrossRef
  45. ↵
    2. Maliszewski, C. R.
    3. G. J.Delespesse
    4. M. A.Schoenborn
    5. R. J.Armitage
    6. W. C.Fanslow
    7. T.Nakajima
    8. E.Baker
    9. G. R.Sutherland
    10. K.Poindexter
    11. C.Birks, et al
    . 1994. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J. Immunol. 153: 3574–3583.
    OpenUrlAbstract
  46. ↵
    2. Koziak, K.
    3. J.Sévigny
    4. S. C.Robson
    5. J. B.Siegel
    6. E.Kaczmarek
    . 1999. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb. Haemost. 82: 1538–1544.
    OpenUrlPubMed
  47. ↵
    2. Schicker, K.
    3. S.Hussl
    4. G. K.Chandaka
    5. K.Kosenburger
    6. J. W.Yang
    7. M.Waldhoer
    8. H. H.Sitte
    9. S.Boehm
    . 2009. A membrane network of receptors and enzymes for adenine nucleotides and nucleosides. Biochim. Biophys. Acta 1793: 325–334.
    OpenUrlCrossRefPubMed
  48. ↵
    2. Braun, N.
    3. J.Sévigny
    4. S. K.Mishra
    5. S. C.Robson
    6. S. W.Barth
    7. R.Gerstberger
    8. K.Hammer
    9. H.Zimmermann
    . 2003. Expression of the ecto-ATPase NTPDase2 in the germinal zones of the developing and adult rat brain. Eur. J. Neurosci. 17: 1355–1364.
    OpenUrlCrossRefPubMed
  49. ↵
    2. Vandenbeuch, A.
    3. C. B.Anderson
    4. J.Parnes
    5. K.Enjyoji
    6. S. C.Robson
    7. T. E.Finger
    8. S. C.Kinnamon
    . 2013. Role of the ectonucleotidase NTPDase2 in taste bud function. Proc. Natl. Acad. Sci. USA 110: 14789–14794.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    2. Feldbrügge, L.
    3. A. C.Moss
    4. E. U.Yee
    5. E.Csizmadia
    6. S.Mitsuhashi
    7. M. S.Longhi
    8. B.Sandhu
    9. H.Stephan
    10. Y.Wu
    11. A. S.Cheifetz, et al
    . 2017. Expression of ecto-nucleoside triphosphate diphosphohydrolases-2 and -3 in the enteric nervous system affects inflammation in experimental colitis and crohn’s disease. J. Crohn’s Colitis 11: 1113–1123.
    OpenUrl
  51. ↵
    2. Belcher, S. M.
    3. A.Zsarnovszky
    4. P. A.Crawford
    5. H.Hemani
    6. L.Spurling
    7. T. L.Kirley
    . 2006. Immunolocalization of ecto-nucleoside triphosphate diphosphohydrolase 3 in rat brain: implications for modulation of multiple homeostatic systems including feeding and sleep-wake behaviors. Neuroscience 137: 1331–1346.
    OpenUrlCrossRefPubMed
  52. ↵
    2. Saunders, D. C.
    3. M.Brissova
    4. N.Phillips
    5. S.Shrestha
    6. J. T.Walker
    7. R.Aramandla
    8. G.Poffenberger
    9. D. K.Flaherty
    10. K. P.Weller
    11. J.Pelletier, et al
    . 2019. Ectonucleoside triphosphate diphosphohydrolase-3 antibody targets adult human pancreatic β cells for in vitro and in vivo analysis. Cell Metab. 29: 745–754.e4.
    OpenUrlCrossRefPubMed
  53. ↵
    2. Lavoie, E. G.
    3. M.Fausther
    4. G.Kauffenstein
    5. F.Kukulski
    6. B. M.Künzli
    7. H.Friess
    8. J.Sévigny
    . 2010. Identification of the ectonucleotidases expressed in mouse, rat, and human Langerhans islets: potential role of NTPDase3 in insulin secretion. Am. J. Physiol. Endocrinol. Metab. 299: E647–E656.
    OpenUrlCrossRefPubMed
  54. ↵
    2. Burch, L. H.
    3. M.Picher
    . 2006. E-NTPDases in human airways: regulation and relevance for chronic lung diseases. Purinergic Signal. 2: 399–408.
    OpenUrlCrossRefPubMed
  55. ↵
    2. Fausther, M.
    3. J.Pelletier
    4. C. M.Ribeiro
    5. J.Sévigny
    6. M.Picher
    . 2010. Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. Am. J. Physiol. Lung Cell. Mol. Physiol. 298: L804–L818.
    OpenUrlCrossRefPubMed
  56. ↵
    2. Strnad, P.
    3. F.Tacke
    4. A.Koch
    5. C.Trautwein
    . 2016. Liver - guardian, modifier and target of sepsis. Nat. Rev. Gastroenterol. Hepatol. 14: 55–66.
    OpenUrl
  57. ↵
    2. Yeung, G.
    3. J. J.Mulero
    4. D. W.McGowan
    5. S. S.Bajwa
    6. J. E.Ford
    . 2000. CD39L2, a gene encoding a human nucleoside diphosphatase, predominantly expressed in the heart. Biochemistry 39: 12916–12923.
    OpenUrlCrossRefPubMed
  58. ↵
    2. Mulero, J. J.
    3. G.Yeung
    4. S. T.Nelken
    5. J. E.Ford
    . 1999. CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates. J. Biol. Chem. 274: 20064–20067.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    2. Abeijon, C.
    3. C. B.Hirschberg
    . 1992. Topography of glycosylation reactions in the endoplasmic reticulum. Trends Biochem. Sci. 17: 32–36.
    OpenUrlCrossRefPubMed
  60. ↵
    2. Trombetta, E. S.
    3. A.Helenius
    . 1999. Glycoprotein reglucosylation and nucleotide sugar utilization in the secretory pathway: identification of a nucleoside diphosphatase in the endoplasmic reticulum. EMBO J. 18: 3282–3292.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    2. Páez, J. G.
    3. J. A.Recio
    4. A.Rouzaut
    5. V.Notario
    . 2001. Identity between the PCPH proto-oncogene and the CD39L4 (ENTPD5) ectonucleoside triphosphate diphosphohydrolase gene. Int. J. Oncol. 19: 1249–1254.
    OpenUrlPubMed
  62. ↵
    2. O’Keeffe, M. G.
    3. P. R.Thorne
    4. G. D.Housley
    5. S. C.Robson
    6. S. M.Vlajkovic
    . 2010. Distribution of NTPDase5 and NTPDase6 and the regulation of P2Y receptor signalling in the rat cochlea. Purinergic Signal. 6: 249–261.
    OpenUrlCrossRefPubMed
  63. ↵
    2. Braun, N.
    3. S.Fengler
    4. C.Ebeling
    5. J.Servos
    6. H.Zimmermann
    . 2000. Sequencing, functional expression and characterization of rat NTPDase6, a nucleoside diphosphatase and novel member of the ecto-nucleoside triphosphate diphosphohydrolase family. Biochem. J. 351: 639–647.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    2. Deaglio, S.
    3. S. C.Robson
    . 2011. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 61: 301–332.
    OpenUrlCrossRefPubMed
  65. ↵
    2. Grubišić, V.
    3. A. L.Perez-Medina
    4. D. E.Fried
    5. J.Sévigny
    6. S. C.Robson
    7. J. J.Galligan
    8. B. D.Gulbransen
    . 2019. NTPDase1 and -2 are expressed by distinct cellular compartments in the mouse colon and differentially impact colonic physiology and function after DSS colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 317: G314–G332.
    OpenUrl
  66. ↵
    2. O’Keeffe, M. G.
    3. P. R.Thorne
    4. G. D.Housley
    5. S. C.Robson
    6. S. M.Vlajkovic
    . 2012. Hair cell specific NTPDase6 immunolocalisation in vestibular end organs: potential role of purinergic signaling in vestibular sensory transduction. J. Vestib. Res. 22: 213–219.
    OpenUrl
  67. ↵
    2. Dombrowski, K. E.
    3. Y.Ke
    4. K. A.Brewer
    5. J. A.Kapp
    . 1998. Ecto-ATPase: an activation marker necessary for effector cell function. Immunol. Rev. 161: 111–118.
    OpenUrlCrossRefPubMed
  68. ↵
    2. Sakowicz-Burkiewicz, M.
    3. M.Grden
    4. I.Maciejewska
    5. A.Szutowicz
    6. T.Pawelczyk
    . 2013. High glucose impairs ATP formation on the surface of human peripheral blood B lymphocytes. Int. J. Biochem. Cell Biol. 45: 1246–1254.
    OpenUrlCrossRefPubMed
  69. ↵
    2. Langston, H. P.
    3. Y.Ke
    4. A. T.Gewirtz
    5. K. E.Dombrowski
    6. J. A.Kapp
    . 2003. Secretion of IL-2 and IFN-gamma, but not IL-4, by antigen-specific T cells requires extracellular ATP. J. Immunol. 170: 2962–2970.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    2. Cohen, H. B.
    3. K. T.Briggs
    4. J. P.Marino
    5. K.Ravid
    6. S. C.Robson
    7. D. M.Mosser
    . 2013. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 122: 1935–1945.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    2. Zanin, R. F.
    3. E.Braganhol
    4. L. S.Bergamin
    5. L. F.Campesato
    6. A. Z.Filho
    7. J. C.Moreira
    8. F. B.Morrone
    9. J.Sévigny
    10. M. R.Schetinger
    11. A. T.de Souza Wyse
    12. A. M.Battastini
    . 2012. Differential macrophage activation alters the expression profile of NTPDase and ecto-5'-nucleotidase. PLoS One 7: e31205.
    OpenUrlCrossRefPubMed
  72. ↵
    2. Uhlén, M.
    3. L.Fagerberg
    4. B. M.Hallström
    5. C.Lindskog
    6. P.Oksvold
    7. A.Mardinoglu
    8. Å.Sivertsson
    9. C.Kampf
    10. E.Sjöstedt
    11. A.Asplund, et al
    . 2015. Proteomics. Tissue-based map of the human proteome. Science 347: 1260419.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    2. Figueiredo, A. B.
    3. M. C.Souza-Testasicca
    4. L. C. C.Afonso
    . 2016. Purinergic signaling and infection by Leishmania: A new approach to evasion of the immune response. Biomed. J. 39: 244–250.
    OpenUrl
  74. ↵
    2. Oliveira, S. D.
    3. N. F.Oliveira
    4. J. R.Meyer-Fernandes
    5. L. E.Savio
    6. F. G.Ornelas
    7. Z. S.Ferreira
    8. R.Coutinho-Silva
    9. C. L.Silva
    . 2016. Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y1 receptors. Vascul. Pharmacol. 82: 66–72.
    OpenUrl
  75. ↵
    2. Savio, L. E. B.
    3. P.de Andrade Mello
    4. V. R.Figliuolo
    5. T. F.de Avelar Almeida
    6. P. T.Santana
    7. S. D. S.Oliveira
    8. C. L. M.Silva
    9. L.Feldbrügge
    10. E.Csizmadia
    11. R. D.Minshall, et al
    . 2017. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury. J. Hepatol. 67: 716–726.
    OpenUrlCrossRef
  76. ↵
    2. Bertoncheli, C. M.
    3. C. E.Zimmermann
    4. J. A.Jaques
    5. C. A.Leal
    6. J. B.Ruchel
    7. B. C.Rocha
    8. K. V.Pinheiro
    9. V. C.Souza
    10. D. R.Stainki
    11. S. C.Luz, et al
    . 2012. Increased NTPDase activity in lymphocytes during experimental sepsis. ScientificWorldJournal 2012: 941906.
    OpenUrl
  77. ↵
    2. Lavoie, E. G.
    3. B. D.Gulbransen
    4. M.Martín-Satué
    5. E.Aliagas
    6. K. A.Sharkey
    7. J.Sévigny
    . 2011. Ectonucleotidases in the digestive system: focus on NTPDase3 localization. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G608–G620.
    OpenUrlCrossRefPubMed
  78. ↵
    2. Friedman, D. J.
    3. B. M.Künzli
    4. Y. I.A-Rahim
    5. J.Sevigny
    6. P. O.Berberat
    7. K.Enjyoji
    8. E.Csizmadia
    9. H.Friess
    10. S. C.Robson
    . 2009. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 106: 16788–16793.
    OpenUrlAbstract/FREE Full Text
  79. ↵
    2. Crittenden, S.
    3. A.Cheyne
    4. A.Adams
    5. T.Forster
    6. C. T.Robb
    7. J.Felton
    8. G. T.Ho
    9. D.Ruckerl
    10. A. G.Rossi
    11. S. M.Anderton, et al
    . 2018. Purine metabolism controls innate lymphoid cell function and protects against intestinal injury. Immunol. Cell Biol. 96: 1049–1059.
    OpenUrl
  80. ↵
    2. Salem, M.
    3. J.Lecka
    4. J.Pelletier
    5. D.Gomes Marconato
    6. A.Dumas
    7. L.Vallières
    8. G.Brochu
    9. B.Robaye
    10. C.Jobin
    11. J.Sévigny
    . 2021. NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD. Gut. gutjnl-2020-320937.
  81. ↵
    2. Kusu, T.
    3. H.Kayama
    4. M.Kinoshita
    5. S. G.Jeon
    6. Y.Ueda
    7. Y.Goto
    8. R.Okumura
    9. H.Saiga
    10. T.Kurakawa
    11. K.Ikeda, et al
    . 2012. Ecto-nucleoside triphosphate diphosphohydrolase 7 controls Th17 cell responses through regulation of luminal ATP in the small intestine. J. Immunol. 190: 774–783.
    OpenUrl
  82. ↵
    2. Dranoff, J. A.
    3. E. A.Kruglov
    4. J.Toure
    5. N.Braun
    6. H.Zimmermann
    7. D.Jain
    8. A. F.Knowles
    9. J.Sévigny
    . 2004. Ectonucleotidase NTPDase2 is selectively down-regulated in biliary cirrhosis. J. Investig. Med. 52: 475–482.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    2. Feldbrügge, L.
    3. Z. G.Jiang
    4. E.Csizmadia
    5. S.Mitsuhashi
    6. S.Tran
    7. E. U.Yee
    8. S.Rothweiler
    9. K. A.Vaid
    10. J.Sévigny
    11. M.Schmelzle, et al
    . 2017. Distinct roles of ecto-nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in liver regeneration and fibrosis. Purinergic Signal. 14: 37–46.
    OpenUrl
  84. ↵
    2. Borsellino, G.
    3. M.Kleinewietfeld
    4. D.Di Mitri
    5. A.Sternjak
    6. A.Diamantini
    7. R.Giometto
    8. S.Höpner
    9. D.Centonze
    10. G.Bernardi
    11. M. L.Dell’Acqua, et al
    . 2007. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225–1232.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    2. Jakovljevic, M.
    3. I.Lavrnja
    4. I.Bozic
    5. D.Savic
    6. I.Bjelobaba
    7. S.Pekovic
    8. J.Sévigny
    9. N.Nedeljkovic
    10. D.Laketa
    . 2017. Down-regulation of NTPDase2 and ADP-sensitive P2 purinoceptors correlate with severity of symptoms during experimental autoimmune encephalomyelitis. Front. Cell. Neurosci. 11: 333.
    OpenUrl
  86. ↵
    2. Candido, J.
    3. T.Hagemann
    . 2012. Cancer-related inflammation. J. Clin. Immunol. 33(Suppl 1)S79–S84.
    OpenUrl
  87. ↵
    2. Di Virgilio, F.
    3. E.Adinolfi
    . 2016. Extracellular purines, purinergic receptors and tumor growth. Oncogene 36: 293–303.
    OpenUrl
  88. ↵
    2. Feng, L. L.
    3. Y. Q.Cai
    4. M. C.Zhu
    5. L. J.Xing
    6. X.Wang
    . 2020. The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int. 20: 110.
    OpenUrl
  89. ↵
    2. Martins, I.
    3. A.Tesniere
    4. O.Kepp
    5. M.Michaud
    6. F.Schlemmer
    7. L.Senovilla
    8. C.Séror
    9. D.Métivier
    10. J. L.Perfettini
    11. L.Zitvogel
    12. G.Kroemer
    . 2009. Chemotherapy induces ATP release from tumor cells. Cell Cycle 8: 3723–3728.
    OpenUrlCrossRefPubMed
  90. ↵
    2. Bergamin, L. S.
    3. E.Braganhol
    4. R. F.Zanin
    5. M. I.Edelweiss
    6. A. M.Battastini
    . 2012. Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview. J. Biomed. Biotechnol. 2012: 959848.
    OpenUrlPubMed
  91. ↵
    2. Wink, M. R.
    3. E.Braganhol
    4. A. S.Tamajusuku
    5. G.Lenz
    6. L. F.Zerbini
    7. T. A.Libermann
    8. J.Sévigny
    9. A. M.Battastini
    10. S. C.Robson
    . 2006. Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) is the dominant ectonucleotidase expressed by rat astrocytes. Neuroscience 138: 421–432.
    OpenUrlCrossRefPubMed
  92. ↵
    2. Braganhol, E.
    3. F.Kukulski
    4. S. A.Lévesque
    5. M.Fausther
    6. E. G.Lavoie
    7. A.Zanotto-Filho
    8. L. S.Bergamin
    9. J.Pelletier
    10. F.Bahrami
    11. F.Ben Yebdri, et al
    . 2015. Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells. Biochim. Biophys. Acta 1852: 120–130.
    OpenUrl
  93. ↵
    2. Morrone, F. B.
    3. D. L.Oliveira
    4. P.Gamermann
    5. J.Stella
    6. S.Wofchuk
    7. M. R.Wink
    8. L.Meurer
    9. M. I.Edelweiss
    10. G.Lenz
    11. A. M.Battastini
    . 2006. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer 6: 226.
    OpenUrlCrossRefPubMed
  94. ↵
    2. Braganhol, E.
    3. F. B.Morrone
    4. A.Bernardi
    5. D.Huppes
    6. L.Meurer
    7. M. I.Edelweiss
    8. G.Lenz
    9. M. R.Wink
    10. S. C.Robson
    11. A. M.Battastini
    . 2009. Selective NTPDase2 expression modulates in vivo rat glioma growth. Cancer Sci. 100: 1434–1442.
    OpenUrlCrossRefPubMed
  95. ↵
    2. Braganhol, E.
    3. R. F.Zanin
    4. A.Bernardi
    5. L. S.Bergamin
    6. A. R.Cappellari
    7. L. F.Campesato
    8. F. B.Morrone
    9. M. M.Campos
    10. J. B.Calixto
    11. M. I.Edelweiss, et al
    . 2011. Overexpression of NTPDase2 in gliomas promotes systemic inflammation and pulmonary injury. Purinergic Signal. 8: 235–243.
    OpenUrl
  96. ↵
    2. Blánquez, M. J.
    3. M. I.Arenas
    4. I.Conde
    5. O. M.Tirado
    6. R.Paniagua
    7. V.Notario
    . 2004. Deregulated expression of the PCPH proto-oncogene in human breast cancers. Int. J. Oncol. 25: 821–830.
    OpenUrlPubMed
  97. ↵
    2. Villar, J.
    3. H. S.Quadri
    4. I.Song
    5. Y.Tomita
    6. O. M.Tirado
    7. V.Notario
    . 2009. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res. 69: 102–110.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    2. Stella, J.
    3. L.Bavaresco
    4. E.Braganhol
    5. L.Rockenbach
    6. P. F.Farias
    7. M. R.Wink
    8. A. A.Azambuja
    9. C. H.Barrios
    10. F. B.Morrone
    11. A. M.Oliveira Battastini
    . 2010. Differential ectonucleotidase expression in human bladder cancer cell lines. Urol. Oncol. 28: 260–267.
    OpenUrlCrossRefPubMed
  99. ↵
    2. Read, R.
    3. G.Hansen
    4. J.Kramer
    5. R.Finch
    6. L.Li
    7. P.Vogel
    . 2009. Ectonucleoside triphosphate diphosphohydrolase type 5 (Entpd5)-deficient mice develop progressive hepatopathy, hepatocellular tumors, and spermatogenic arrest. Vet. Pathol. 46: 491–504.
    OpenUrlCrossRefPubMed
  100. ↵
    2. Recio, J. A.
    3. J. G.Páez
    4. S.Sanders
    5. T.Kawakami
    6. V.Notario
    . 2002. Partial depletion of intracellular ATP mediates the stress-survival function of the PCPH oncoprotein. Cancer Res. 62: 2690–2694.
    OpenUrlAbstract/FREE Full Text
  101. ↵
    2. Rockenbach, L.
    3. E.Braganhol
    4. F.Dietrich
    5. F.Figueiró
    6. M.Pugliese
    7. M. I.Edelweiss
    8. F. B.Morrone
    9. J.Sévigny
    10. A. M.Battastini
    . 2014. NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression. Purinergic Signal. 10: 421–430.
    OpenUrl
  102. ↵
    2. Lecka, J.
    3. I.Gillerman
    4. M.Fausther
    5. M.Salem
    6. M. N.Munkonda
    7. J. P.Brosseau
    8. C.Cadot
    9. M.Martín-Satué
    10. P.d’Orléans-Juste
    11. E.Rousseau, et al
    . 2013. 8-BuS-ATP derivatives as specific NTPDase1 inhibitors. Br. J. Pharmacol. 169: 179–196.
    OpenUrl
  103. ↵
    2. Allard, B.
    3. M. S.Longhi
    4. S. C.Robson
    5. J.Stagg
    . 2017. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol. Rev. 276: 121–144.
    OpenUrlCrossRefPubMed
  104. ↵
    2. Perrot, I.
    3. H. A.Michaud
    4. M.Giraudon-Paoli
    5. S.Augier
    6. A.Docquier
    7. L.Gros
    8. R.Courtois
    9. C.Déjou
    10. D.Jecko
    11. O.Becquart, et al
    . 2019. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 27: 2411–2425.e9.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section